Pharmafile Logo

CVnCoV

Eli Lilly HQ

Lilly expands its immuno-oncology work with $1.8bn CureVac deal

Will work with the German firm to develop ‘next generation’ cancer vaccines

CureVac’s CEO appointed to EC High Level Group

Dr Ingmar Hoerr will advise on Horizon 2020 and future innovation programmes

- PMLiVE

CureVac appoints chief financial officer

Pierre Kemula joins the mRNA company’s management board

Boehringer Ingelheim headquarters

Boehringer signs €465m lung cancer vaccine deal

Licenses CureVac's cancer immunotherapy CV9202

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links